blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2435064

EP2435064 - USE OF HAT INHIBITORS AND TMPRSS2 INHIBITORS AS MEDICAMENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.06.2016
Database last updated on 02.11.2024
Most recent event   Tooltip19.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 21.11.2018  [2018/47]
Applicant(s)For all designated states
Philipps-Universität Marburg
Biegenstrasse 10
35037 Marburg / DE
[2015/34]
Former [2012/14]For all designated states
Philipps-Universität Marburg
Biegenstrasse 10
35037 Marburg / DE
Inventor(s)01 / STEINMETZER, Torsten
Ricarda-Huch-Weg 23
07743 Jena / DE
02 / SIELAFF, Frank
Brunnenstraße 22
35041 Marburg / DE
03 / GARTEN, Wolfgang
Schlangenzahl 28
35392 Gießen / DE
04 / BÖTTCHER, Eva
Ernst-Moritz-Arndt-Straße 6
35039 Marburg / DE
05 / FREUER, Catharina
Reitgasse 13-15
35037 Marburg / DE
06 / MATROSOVICH, Mikhail
Hölderlinstraße 4
35039 Marburg / DE
07 / MATROSOVICH, Tatyana
Hölderlinstraße 4
35039 Marburg / DE
 [2012/14]
Representative(s)Patentanwälte Olbricht Buchhold Keulertz
Partnerschaft mbB
Neue Mainzer Straße 75
60311 Frankfurt am Main / DE
[N/P]
Former [2015/34]Patentanwälte Olbricht Buchhold Keulertz
Partnerschaft mbB
Bettinastrasse 53-55
60325 Frankfurt / DE
Former [2013/43]Patentanwälte Olbricht Buchhold Keulertz
Partnerschaft
Bettinastrasse 53-55
60325 Frankfurt / DE
Former [2012/40]Buchhold, Jürgen, et al
Patentanwälte
Olbricht Buchhold Keulertz & Partner
Bettinastrasse 53-55
60325 Frankfurt am Main / DE
Former [2012/14]Stumpf, Peter
c/o TransMIT GmbH Kerkrader Strasse 3
35394 Gießen / DE
Application number, filing date10729701.227.05.2010
[2015/34]
WO2010EP57334
Priority number, dateDE2009102279427.05.2009         Original published format: DE102009022794
[2012/14]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2010149459
Date:29.12.2010
Language:DE
[2010/52]
Type: A1 Application with search report 
No.:EP2435064
Date:04.04.2012
Language:DE
The application published by WIPO in one of the EPO official languages on 29.12.2010 takes the place of the publication of the European patent application.
[2012/14]
Type: B1 Patent specification 
No.:EP2435064
Date:19.08.2015
Language:DE
[2015/34]
Search report(s)International search report - published on:EP29.12.2010
ClassificationIPC:A61K38/07, A61P35/00, A61P31/12, A61P11/00
[2012/14]
CPC:
A61K31/381 (EP); A61K31/40 (EP); A61K31/426 (EP);
A61K31/44 (EP); A61K38/05 (EP); A61P11/00 (EP);
A61P29/00 (EP); A61P31/12 (EP); A61P35/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/14]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:VERWENDUNG VON HEMMSTOFFEN DER HAT UND TMPRSS2 ALS ARZNEIMITTEL[2012/14]
English:USE OF HAT INHIBITORS AND TMPRSS2 INHIBITORS AS MEDICAMENTS[2012/14]
French:UTILISATION D'INHIBITEURS DE LA HAT ET DE LA TMPRSS2 EN TANT QUE MÉDICAMENTS[2012/14]
Entry into regional phase27.12.2011National basic fee paid 
27.12.2011Designation fee(s) paid 
27.12.2011Examination fee paid 
Examination procedure27.12.2011Examination requested  [2012/14]
16.07.2012Amendment by applicant (claims and/or description)
05.02.2013Despatch of a communication from the examining division (Time limit: M02)
10.04.2013Reply to a communication from the examining division
18.07.2013Despatch of a communication from the examining division (Time limit: M02)
17.09.2013Reply to a communication from the examining division
10.10.2014Communication of intention to grant the patent
13.01.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.03.2015Communication of intention to grant the patent
09.07.2015Fee for grant paid
09.07.2015Fee for publishing/printing paid
09.07.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.02.2013
Opposition(s)20.05.2016No opposition filed within time limit [2016/30]
Fees paidRenewal fee
31.05.2012Renewal fee patent year 03
31.05.2013Renewal fee patent year 04
02.06.2014Renewal fee patent year 05
01.06.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.05.2010
AL19.08.2015
BG19.08.2015
CY19.08.2015
CZ19.08.2015
DK19.08.2015
EE19.08.2015
ES19.08.2015
FI19.08.2015
HR19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
MC19.08.2015
MK19.08.2015
MT19.08.2015
NL19.08.2015
PL19.08.2015
RO19.08.2015
SE19.08.2015
SI19.08.2015
SK19.08.2015
SM19.08.2015
TR19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
[2018/47]
Former [2018/38]HU27.05.2010
BG19.08.2015
CY19.08.2015
CZ19.08.2015
DK19.08.2015
EE19.08.2015
ES19.08.2015
FI19.08.2015
HR19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
MC19.08.2015
MK19.08.2015
MT19.08.2015
NL19.08.2015
PL19.08.2015
RO19.08.2015
SE19.08.2015
SI19.08.2015
SK19.08.2015
SM19.08.2015
TR19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2018/32]HU27.05.2010
CY19.08.2015
CZ19.08.2015
DK19.08.2015
EE19.08.2015
ES19.08.2015
FI19.08.2015
HR19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
MC19.08.2015
MK19.08.2015
MT19.08.2015
NL19.08.2015
PL19.08.2015
RO19.08.2015
SE19.08.2015
SI19.08.2015
SK19.08.2015
SM19.08.2015
TR19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2018/29]HU27.05.2010
CY19.08.2015
CZ19.08.2015
DK19.08.2015
EE19.08.2015
ES19.08.2015
FI19.08.2015
HR19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
MC19.08.2015
MK19.08.2015
NL19.08.2015
PL19.08.2015
RO19.08.2015
SE19.08.2015
SI19.08.2015
SK19.08.2015
SM19.08.2015
TR19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2018/28]HU27.05.2010
CY19.08.2015
CZ19.08.2015
DK19.08.2015
EE19.08.2015
ES19.08.2015
FI19.08.2015
HR19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
MC19.08.2015
MK19.08.2015
NL19.08.2015
PL19.08.2015
RO19.08.2015
SE19.08.2015
SI19.08.2015
SK19.08.2015
SM19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/36]CZ19.08.2015
DK19.08.2015
EE19.08.2015
FI19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
NL19.08.2015
PL19.08.2015
RO19.08.2015
SE19.08.2015
SI19.08.2015
SK19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/23]CZ19.08.2015
DK19.08.2015
EE19.08.2015
FI19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
NL19.08.2015
PL19.08.2015
RO19.08.2015
SE19.08.2015
SK19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/22]CZ19.08.2015
DK19.08.2015
EE19.08.2015
FI19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
NL19.08.2015
PL19.08.2015
SE19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/21]DK19.08.2015
FI19.08.2015
IT19.08.2015
LT19.08.2015
LV19.08.2015
NL19.08.2015
PL19.08.2015
SE19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/20]DK19.08.2015
FI19.08.2015
LT19.08.2015
LV19.08.2015
NL19.08.2015
PL19.08.2015
SE19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/14]FI19.08.2015
LT19.08.2015
LV19.08.2015
NL19.08.2015
PL19.08.2015
SE19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/10]FI19.08.2015
LT19.08.2015
LV19.08.2015
PL19.08.2015
SE19.08.2015
NO19.11.2015
GR20.11.2015
IS19.12.2015
PT21.12.2015
Former [2016/09]FI19.08.2015
LT19.08.2015
LV19.08.2015
NO19.11.2015
GR20.11.2015
Former [2016/08]LT19.08.2015
NO19.11.2015
Former [2016/07]LT19.08.2015
Cited inInternational search[X]WO0196286  (UNIV SCHILLER JENA [DE], et al) [X] 9,10,13 * claims 1-5 * * examples 1,2 *;
 [A]DE102006048300  (HELLSTERN PETER [DE], et al) [A] 1-15 * Verbindungen nach Formel (ll) *;
 [X]EP1182207  (CORVAS INT INC [US]) [X] 9,13 * paragraph [0149] * * examples 1-98 *;
 [X]WO03076391  (CURACYTE AG [DE], et al) [X] 9,13 * claims 1-20 *;
 [X]US6797504  (MADISON EDWIN L [US], et al) [X] 9,13 * paragraph [0002] *;
 [A]  - SCHWEINITZ ANDREA ET AL, "Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents", JOURNAL OF BIOLOGICAL CHEMISTRY, (20040806), vol. 279, no. 32, ISSN 0021-9258, pages 33613 - 33622, XP002597718 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.m314151200
 [IA]  - BANKE INGO J ET AL, "Increase of anti-metastatic efficacy by selectivity-but not affinity-optimization of synthetic serine protease inhibitors", BIOLOGICAL CHEMISTRY, WALTER DE GRUYTER GMBH & CO, BERLIN, DE, (20031001), vol. 384, no. 10-11, ISSN 1431-6730, pages 1515 - 1525, XP009137831 [I] 9,13 * the whole document * [A] 1-8,10-12,14,15
Examination   - ETTMAYER PETER ET AL, "Lessons learned from marketed and investigational prodrugs", JOURNAL OF MEDICINAL CHEMISTRY, (20040506), vol. 47, no. 10, doi:doi:10.1021/jm0303812, ISSN 0022-2623, pages 2393 - 2404, XP001537347

DOI:   http://dx.doi.org/10.1021/jm0303812
    - MATSUSHIMA RIE ET AL, "Human airway trypsin-like protease stimulates human bronchial fibroblast proliferation in a protease-activated receptor-2-dependent pathway", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, (200602), vol. 290, no. 2, ISSN 1040-0605, pages L385 - L395
    - SIELAFF FRANK ET AL, "Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (201108), vol. 21, no. 16, doi:doi:10.1016/j.bmcl.2011.06.033, pages 4860 - 4864, XP028267764

DOI:   http://dx.doi.org/10.1016/j.bmcl.2011.06.033
by applicant   - YASUOKA ET AL., AM. J. RESPIR. CELL MOL. BI- OL., (1997), vol. 16, pages 300 - 308
    - BÖTTCHER ET AL., J. VIROLO- GY, (2006), vol. 80, pages 9896 - 9898
    - MATSUSHIMA ET AL., AM J. PHYSIOL LUNG CELL MOL PHYSIOL., (2006), vol. 290, pages L385 - L395
    - CHOKKI ET AL., AM. J. RESPIR. CELL MOL. BIOL., (2004), vol. 30, pages 470 - 478
    - PAOLINI- GIACOBINO, GENOMICS, (1997), vol. 44, pages 309 - 320
    - BÖTTCHER ET AL., J. VIROLOGY, (2006), vol. 80, pages 9896 - 9898
    - CHAIPAN ET AL., J. VIROLOGY, (2009), vol. 83, pages 3200 - 3211
    - SHIROGANE ET AL., J. VIROLOGY, (2008), vol. 82, pages 8942 - 8946
    - AFAR ET AL., CANCER RES., (2001), vol. 61, pages 1686 - 1692
    - VARAALA ET AL., INT. J. CANCER, (2001), vol. 94, pages 705 - 710
    - LUCAS ET AL., J. PATHOLOGY, (2008), vol. 215, pages 118 - 125
    - SCHWEINITZ ET AL., J. BIOL. CHEM., (2004), vol. 279, pages 33613 - 336122
    - SCHWEINITZ ET AL., MEDICINAL CHEMISTRY, (2006), vol. 2, pages 349 - 361
    - STÜRZEBE- CHER ET AL., CHEMMEDCHEM, (2007), vol. 2, pages 1043 - 1053
    - HELLSTERN ET AL., J. THROMB. HA- EMOST., (2007), vol. 5, pages 2119 - 2126
    - SCH- ECHTER; BERGER, BIOCHEM. BIOPHYS. RES. COMM., (1967), vol. 27, page 157
    - SCHWEINITZ ET AL., MEDICINAL CHE- MISTRY, (2006), vol. 2, pages 349 - 361
    - STÜRZEBECHER ET AL., CHEMMEDCHEM, (2007), vol. 2, pages 1043 - 1053
    - HELLSTERN ET AL., J. THROMB. HAEMOST., (2007), vol. 5, pages 2119 - 2126
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.